REFERENCES
1. Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries. Eur Heart J. 2005;26:2422-34.
2. Jin Y, Wang K, Xiao B, et al. Global burden of atrial fibrillation/flutter due to high systolic blood pressure from 1990 to 2019: estimates from the global burden of disease study 2019. J Clin Hypertens. 2022;24:1461-72.
3. Sethi NJ, Safi S, Feinberg J, Nielsen EE, Gluud C, Jakobsen JC. Digoxin versus placebo, no intervention, or other medical interventions for atrial fibrillation and atrial flutter: a protocol for a systematic review with meta-analysis and trial sequential analysis. Syst Rev. 2017;6:71.
4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991;22:983-8.
5. Suomalainen OP, Martinez-majander N, Broman J, et al. Stroke in patients with atrial fibrillation: epidemiology, screening, and prognosis. J Clin Med. 2023;13:30.
6. Srichawla BS, Hamel AP, Cook P, et al. Is catheter ablation associated with preservation of cognitive function? Front. Neurol. 2024;14:1302020.
7. Lucà F, Abrignani MG, Oliva F, et al. Multidisciplinary approach in atrial fibrillation: as good as gold. J Clin Med. 2024;13:4621.
8. Kong X, Li M, He L, et al. Burden of atrial fibrillation and atrial flutter from 1990 to 2021 in China: global burden of disease study 2021 update. Pacing Clin Electrophysiol. 2025;48:447-54.
9. Wang Z, Chen Z, Wang X, et al. The disease burden of atrial fibrillation in China from a national cross-sectional survey. Am J Cardiol. 2018;122:793-8.
10. Zhang C, Zhang X, Zhou R, et al. Secular trend in disease burden of atrial fibrillation/flutter in China from 1992 to 2021 and its projection in 25 years. BMC Public Health. 2025;25:2064.
11. Murray CJL, Abbafati C, Abbas KM, et al. Five insights from the global burden of disease study 2019. Lancet. 2020;396:1135-59.
12. Yang G, Ouyang H, Zhao Z, et al. Discrepancies in neglected tropical diseases burden estimates in China: comparative study of real-world data and global burden of disease 2021 data (2004-2020). BMJ. 2025;388:e080969.
13. Dong X, Wang B, Hou F, et al. Global burden of atrial fibrillation/atrial flutter and its attributable risk factors from 1990 to 2019. EP Europac. 2023;25:793-803.
14. Pellicer PS, Tamayo RG, López VN. Reducing test request for anti-thyroglobulin and anti-thyroid peroxidase antibodies: trends before and after interventions based on rejection rules and profile management. Biochemia Medica. 2018;28:030709.
15. Rosenberg PS, Check DP, Anderson WF. A web tool for age-period-cohort analysis of cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev. 2014;23:2296-302.
16. Xu S, Liu Z, Tang M, Xu C. Burden, risk factors, and projections of ischemic heart disease in China (1990-2021): findings from the 2021 GBD study. Front. Cardiovasc. Med. 2025;12:1549147.
17. Bul M, Shaikh F, Mcdonagh J, Ferguson C. Frailty and oral anticoagulant prescription in adults with atrial fibrillation: a systematic review. Aging Med. 2022;6:195-206.
18. Kannel WB, Abbott RD, Savage DD, Mcnamara PM. Epidemiologic features of chronic atrial fibrillation: the framingham study. N Engl J Med. 1982;306:1018-22.
19. Von Olshausen G, Schwieler J, Bastani H, et al. Incidence of atrial fibrillation and its association with long-term outcome in patients with an accessory pathway. Front Cardiovasc Med. 2025;12:1639305.
20. Goette A, Corradi D, Dobrev D, et al. Atrial cardiomyopathy revisited-evolution of a concept: a clinical consensus statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), the Asian Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS). Europace. 2024;26:euae204.
21. Diallo EH, Brouillard P, Raymond JM, Liberman M, Duceppe E, Potter BJ. Predictors and impact of postoperative atrial fibrillation following thoracic surgery: a state‐of‐the‐art review. Anaesthesia. 2023;78:491-500.
22. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev. 2011;91:265-325.
23. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349:1019-26.
24. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667-77.
25. Andreotti F, Geisler T, Collet J, et al. Acute, periprocedural and longterm antithrombotic therapy in older adults. Eur Heart J. 2023;44:262-79.
26. Schukraft S, Huwyler T, Ottiger-mankaka C, et al. Bleeding risk profile in patients on oral anticoagulation undergoing percutaneous coronary interventions: a prospective 24 months cohort study. Front. Cardiovasc. Med. 2021;8:589426.
27. Capolongo A, De Sio V, Gragnano F, et al. Long-term antithrombotic therapy in patients with atrial fibrillation and percutaneous coronary intervention. JCM. 2025;14:3713.
28. Gragnano F, Van Klaveren D, Heg D, et al. Derivation and validation of the PRECISE-HBR score to predict bleeding after percutaneous coronary intervention. Circulation. 2025;151:343-55.
29. Scalvini S, Piepoli M, Zanelli E, Volterrani M, Giordano A, Glisenti F. Incidence of atrial fibrillation in an Italian population followed by their GPs through a telecardiology service. Int J Cardiol. 2005;98:215-20.
30. Srinivasan NT, Schilling RJ. ; Barts Heart Centre, St Bartholomew’s Hospital, London, UK. Sudden cardiac death and arrhythmias. Arrhythm Electrophysiol Rev. 2018;7:111.
31. Vitolo M, Ziveri V, Gozzi G, et al. DIGItal health literacy after COVID-19 outbreak among frail and non-frail cardiology patients: the DIGI-COVID study. J Pers Med. 2022;13:99.
32. Simonson JK, Anderson M, Polacek C, Klump E, Haque SN. Characterizing real-world implementation of consumer wearables for the detection of undiagnosed atrial fibrillation in clinical practice: targeted literature review. JMIR Cardio. 2023;7:e47292.
33. Gowd BMP, Thompson PD. Effect of female sex on cardiac arrhythmias. Cardiol Rev. 2012;20:297-303.
34. Ko D, Rahman F, Martins MAP, et al. Atrial fibrillation in women: treatment. Nat Rev Cardiol. 2016;14:113-24.
35. Dagres N, Nieuwlaat R, Vardas PE, et al. Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe. J Am Coll Cardiol. 2007;49:572-7.
36. Kim YG, Han K, Choi J, et al. Non-genetic risk factors for atrial fibrillation are equally important in both young and old age: a nationwide population-based study. Eur J Prev Cardiol. 2021;28:666-76.
